{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000201","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.244954+00:00","generated_at":"2026-06-27T19:44:38.107263+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amarin reports preliminary 2021 revenue ~$580M, appoints Per Wold-Olsen to board","bullets":["Full-year 2021 net revenue ~$580M; Q4 revenue ~$140M, stable vs Q3.","Ended 2021 with ~$490M cash/investments and no debt.","Plans to develop fixed-dose combination of VASCEPA and a statin.","Per Wold-Olsen appointed to Board effective Jan 10, 2022; receives $540K in equity awards.","2022 revenue guidance not provided due to COVID/generic uncertainty; US ops expect positive contribution margin."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000201","json":"https://secwatch.observer/filing/0000950170-22-000201.json","markdown":"https://secwatch.observer/filing/0000950170-22-000201.md","text":"https://secwatch.observer/filing/0000950170-22-000201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017022000201/0000950170-22-000201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017022000201/amrn-20220109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:44:38.107263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bb3d276f5","claim":"Per Wold-Olsen was appointed as Director at AMARIN CORP PLCUK.","evidence_excerpt":"On January 9, 2022, the Board, in accordance with the Company’s articles of association and upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Per Wold-Olsen as a Director of the Company, effective as of January 10, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017022000201/0000950170-22-000201-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}